U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06797999) titled 'First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma' on Jan. 16.
Brief Summary: The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Metastatic Soft Tissue Sarcoma
Unresectable Soft Tissue Sarcoma
Intervention:
BIOLOGICAL: Antibody-drug conjugate (ADC)
ADCE-D01 is an antibody-drug conjugate (ADC) composed of an anti-urokinase plasminogen activator receptor-associated protein (uPARAP) antibody, AB-004, conjugated to a topoisomerase I inhibitor, P1021, via a protease cleavage tetra-peptide linker.
Recruitment Sta...